Reinsurer Swiss Re issues longevity drug guidelines
Select your language
Generated with artificial intelligence.
Listening:
Reinsurer Swiss Re issues longevity drug guidelines
Reinsurer Swiss Re has introduced guidelines for so-called longevity drugs. Specifically, the guidelines target drugs such as metformin and rapamycin, which were originally developed for other purposes and are used by certain individuals to prolong their lives.
+Get the most important news from Switzerland in your inbox
As the long-term effects are still uncertain, Swiss Re has now introduced guidelines for underwriters to assess longevity drugs that show signs of being used, the company announced on Monday. The adjustment is part of the update to the Swiss Re Life Guide from August 2025.
In addition to life-prolonging drugs, the guide has also been expanded to include an improved calculator for chronic kidney disease and prostate cancer risks, as well as enhanced medical risk assessment tools.
More
The Basel researcher whose work triggered a longevity revolution
According to Swiss Re, the Life Guide is used by over 800 insurance companies in more than 100 countries, which use it to conduct around 23 million risk assessment inquiries annually.
Translated from German by DeepL/jdp
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.